Biotechnology US clinical stage biotech Praxis Precision Medicines’ shares closed up nearly 5% yesterday and rose a further 2.3% to $2.25 pre-market, on the news of a strategic collaboration with Belgium’s UCB, based on Praxis’ PRAX-020 program, for the discovery of small molecule therapeutics as potential treatments of KCNT1 related epilepsies. 14 December 2022